Abstract
Schizophrenia is a devastating, chronic brain disorder afflicting about 1% percent of the population. The etiology, neuropathology, and pathophysiology of schizophrenia remain elusive. Intense research has been conducted in order to identify specific biological markers of schizophrenia. The gas nitric oxide (NO) is an important signaling molecule involved in many cellular events that take place in the cardiovascular, immune and nervous systems of animals. This present review aims to show that NO and its metabolites play eminent roles in schizophrenia and have a significant influence on our understanding of the development, progression and, possibly, treatment of the disease. Special emphasis is given to aspects of genetic linkage between NO generating and modulating proteins and schizophrenia, and the impact of NO metabolism on processes known to be disturbed in this neuropsychiatric disorder (i. e., nerve cell migration, formation and maintenance of synapses, N-methyl-D-aspartic acid receptor mediated neurotransmission, adult hippocampal neurogenesis, membrane pathology and cognitive abilities). Although certain alterations of brain NO metabolism are not unique to, or indicative of, schizophrenia, their modulation might be a promising therapeutic option for the future.
Keywords: Schizophrenia, Nitric oxide, Nitric oxide synthase(s), Brain, Genetics, Immunohistochemistry, Biochemistry, Cerebrospinal fluid, Blood, Animal models, Therapy, eNOS, iNOs, nNOS, CAPON
CNS & Neurological Disorders - Drug Targets
Title: Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
Volume: 10 Issue: 7
Author(s): Hans-Gert Bernstein, Gerburg Keilhoff, Johann Steiner, Henrik Dobrowolny and Bernhard Bogerts
Affiliation:
Keywords: Schizophrenia, Nitric oxide, Nitric oxide synthase(s), Brain, Genetics, Immunohistochemistry, Biochemistry, Cerebrospinal fluid, Blood, Animal models, Therapy, eNOS, iNOs, nNOS, CAPON
Abstract: Schizophrenia is a devastating, chronic brain disorder afflicting about 1% percent of the population. The etiology, neuropathology, and pathophysiology of schizophrenia remain elusive. Intense research has been conducted in order to identify specific biological markers of schizophrenia. The gas nitric oxide (NO) is an important signaling molecule involved in many cellular events that take place in the cardiovascular, immune and nervous systems of animals. This present review aims to show that NO and its metabolites play eminent roles in schizophrenia and have a significant influence on our understanding of the development, progression and, possibly, treatment of the disease. Special emphasis is given to aspects of genetic linkage between NO generating and modulating proteins and schizophrenia, and the impact of NO metabolism on processes known to be disturbed in this neuropsychiatric disorder (i. e., nerve cell migration, formation and maintenance of synapses, N-methyl-D-aspartic acid receptor mediated neurotransmission, adult hippocampal neurogenesis, membrane pathology and cognitive abilities). Although certain alterations of brain NO metabolism are not unique to, or indicative of, schizophrenia, their modulation might be a promising therapeutic option for the future.
Export Options
About this article
Cite this article as:
Bernstein Hans-Gert, Keilhoff Gerburg, Steiner Johann, Dobrowolny Henrik and Bogerts Bernhard, Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy, CNS & Neurological Disorders - Drug Targets 2011; 10 (7) . https://dx.doi.org/10.2174/187152711798072392
DOI https://dx.doi.org/10.2174/187152711798072392 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pathological Gambling: Update on Decision Making and Neuro-functional Studies in Clinical Samples
Current Pharmaceutical Design Nanotechnology Driven Approaches for the Management of Parkinson’s Disease: Current Status and Future Perspectives
Current Drug Metabolism An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Current Pharmaceutical Design Cognitive Impairment and Dementia in Patients with Parkinson Disease
Current Topics in Medicinal Chemistry Adenosine and Related Drugs in Brain Diseases: Present and Future in Clinical Trials
Current Topics in Medicinal Chemistry Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson´s Disease
Current Neuropharmacology Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders
Current Topics in Medicinal Chemistry α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
Current Pharmaceutical Design On the Diversity of Oxidative Bioactivation Reactions on Nitrogen- Containing Xenobiotics
Current Drug Metabolism Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design AMPA Receptor Potentiators: Application for Depression and Parkinsons Disease
Current Drug Targets Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective
Current Neuropharmacology Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Anti-NMDA Receptor Encephalitis: Efficacy of Treatment for Male Patients and miRNA Biomarker
Current Medicinal Chemistry Depot Based Drug Delivery System for the Management of Depression
Current Drug Delivery Burden of Bronchiectasis in Indigenous Peoples - How Can it be Improved?
Current Pediatric Reviews